Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Sector Gamma AS

Sector Gamma AS reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 197,500 shares of the biopharmaceutical company's stock after selling 91,663 shares during the quarter. Gilead Sciences makes up 6.3% of Sector Gamma AS's portfolio, making the stock its 4th largest holding. Sector Gamma AS's holdings in Gilead Sciences were worth $18,243,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of GILD. State Street Corp boosted its position in shares of Gilead Sciences by 1.4% during the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock valued at $5,044,795,000 after acquiring an additional 841,776 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares in the last quarter. FMR LLC grew its stake in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares during the period. Geode Capital Management LLC raised its holdings in shares of Gilead Sciences by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock worth $2,302,119,000 after buying an additional 574,421 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Gilead Sciences by 3.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company's stock worth $739,217,000 after buying an additional 249,804 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Remove Ads

Insider Activity

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 302,785 shares of company stock worth $30,503,250 over the last quarter. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on GILD shares. Royal Bank of Canada increased their price objective on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald reissued a "neutral" rating and set a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Oppenheimer lifted their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. Finally, Bank of America increased their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $104.52.

Gilead Sciences Trading Up 1.1 %

Shares of NASDAQ GILD traded up $1.15 during midday trading on Tuesday, reaching $107.89. 8,444,141 shares of the stock were exchanged, compared to its average volume of 6,800,034. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a market capitalization of $134.36 billion, a price-to-earnings ratio of 291.59, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business has a 50-day simple moving average of $104.35 and a two-hundred day simple moving average of $94.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.